G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 4.75 HKD 0.21% Market Closed
Market Cap: 16.9B HKD
Have any thoughts about
Grand Pharmaceutical Group Ltd?
Write Note

Grand Pharmaceutical Group Ltd
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Grand Pharmaceutical Group Ltd
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
G
Grand Pharmaceutical Group Ltd
HKEX:512
Deferred Income Tax
HK$289.7m
CAGR 3-Years
16%
CAGR 5-Years
10%
CAGR 10-Years
20%
U
United Laboratories International Holdings Ltd
HKEX:3933
Deferred Income Tax
ÂĄ368.3m
CAGR 3-Years
37%
CAGR 5-Years
7%
CAGR 10-Years
-7%
Sino Biopharmaceutical Ltd
HKEX:1177
Deferred Income Tax
ÂĄ797.2m
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
30%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Deferred Income Tax
ÂĄ1.1B
CAGR 3-Years
-14%
CAGR 5-Years
-9%
CAGR 10-Years
15%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Deferred Income Tax
HK$1.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
16.9B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
4.74 HKD
Fairly Valued
Intrinsic Value
Price
G

See Also

What is Grand Pharmaceutical Group Ltd's Deferred Income Tax?
Deferred Income Tax
289.7m HKD

Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Deferred Income Tax amounts to 289.7m HKD.

What is Grand Pharmaceutical Group Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
20%

Over the last year, the Deferred Income Tax growth was 34%. The average annual Deferred Income Tax growth rates for Grand Pharmaceutical Group Ltd have been 16% over the past three years , 10% over the past five years , and 20% over the past ten years .

Back to Top